Aristotle Capital Boston LLC Increases Stock Position in Haemonetics Corporation $HAE

Aristotle Capital Boston LLC boosted its holdings in Haemonetics Corporation (NYSE:HAE) by 11.4% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 404,162 shares of the medical instruments supplier’s stock after buying an additional 41,215 shares during the period. Aristotle Capital Boston LLC’s holdings in Haemonetics were worth $19,699,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of HAE. AQR Capital Management LLC raised its stake in shares of Haemonetics by 372.8% in the third quarter. AQR Capital Management LLC now owns 2,128,878 shares of the medical instruments supplier’s stock worth $102,814,000 after purchasing an additional 1,678,630 shares during the last quarter. River Road Asset Management LLC lifted its holdings in shares of Haemonetics by 18.7% during the second quarter. River Road Asset Management LLC now owns 1,655,676 shares of the medical instruments supplier’s stock valued at $122,586,000 after purchasing an additional 260,624 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Haemonetics by 1.9% during the second quarter. Geode Capital Management LLC now owns 1,244,624 shares of the medical instruments supplier’s stock valued at $92,873,000 after buying an additional 23,257 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in Haemonetics by 2.5% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,099,519 shares of the medical instruments supplier’s stock worth $53,587,000 after buying an additional 26,763 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC increased its holdings in Haemonetics by 11.7% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,060,790 shares of the medical instruments supplier’s stock worth $51,777,000 after buying an additional 111,307 shares in the last quarter. Institutional investors own 99.67% of the company’s stock.

Haemonetics Stock Up 0.7%

HAE stock opened at $59.93 on Friday. The company has a market cap of $2.78 billion, a price-to-earnings ratio of 16.51, a P/E/G ratio of 1.25 and a beta of 0.28. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.15 and a current ratio of 1.75. The business’s 50-day moving average is $66.67 and its two-hundred day moving average is $64.72. Haemonetics Corporation has a fifty-two week low of $47.31 and a fifty-two week high of $87.32.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Thursday, February 5th. The medical instruments supplier reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.27 by $0.04. Haemonetics had a return on equity of 27.32% and a net margin of 13.31%.The business had revenue of $338.97 million during the quarter, compared to the consensus estimate of $331.90 million. During the same period in the previous year, the company posted $1.19 EPS. The business’s quarterly revenue was down 2.7% compared to the same quarter last year. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS. As a group, analysts forecast that Haemonetics Corporation will post 4.55 earnings per share for the current year.

Wall Street Analysts Forecast Growth

HAE has been the topic of several research analyst reports. CJS Securities upgraded shares of Haemonetics to a “strong-buy” rating in a research note on Thursday, December 11th. Weiss Ratings reiterated a “hold (c)” rating on shares of Haemonetics in a research note on Monday, December 29th. Mizuho decreased their price objective on shares of Haemonetics from $90.00 to $80.00 and set an “outperform” rating for the company in a report on Friday, February 6th. BTIG Research restated a “buy” rating and set a $88.00 price objective on shares of Haemonetics in a research report on Friday, February 6th. Finally, Barrington Research set a $94.00 target price on shares of Haemonetics in a report on Friday, February 6th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $83.89.

Haemonetics Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.